Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy.
In this study, high-risk patients with hypertrophic cardiomyopathy were treated with an implantable defibrillator. Long-term follow-up analysis showed the efficacy of implantable defibrillator therapy, with patients having an appropriate device intervention at a rate of 11%/year, thereby preventing sudden death in an Australian population.
Jayatilleke
Irandi
I
Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, Newtown, New South Wales, Australia.
Doolan
Alessandra
A
Ingles
Jodie
J
McGuire
Mark
M
Booth
Virginia
V
Richmond
David R
DR
Semsarian
Christopher
C
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D001315:Australia; D002312:Cardiomyopathy, Hypertrophic / Q000453:epidemiology / Q000628:therapy*; D017147:Defibrillators, Implantable; D005500:Follow-Up Studies; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000453:epidemiology / Q000628:therapy; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology; D012307:Risk Factors; D013015:Sotalol / Q000627:therapeutic use; D013995:Time; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D013015:Sotalol